News (59)

BioNTech : Joint report of the Management Board of BioNTech SE and the management of BioNTech Collaborations GmbH on the domination and profit and loss transfer agreement pursuant to Section 293a AktG PU
BioNTech : Annual Report 2023 with the Consolidated Financial Statements as of 31 December 2023, the Combined Management Report for BioNTech SE and the Group and the Report of the Supervisory Board for the 2023 financial year PU
BioNTech : Compensation Report for the 2023 financial year PU
Tonies : CVs of tonies SE Supervisory Board members according to Election Proposal PU
Tonies : Voting Form PU
Tonies : Remuneration Report 2023 PU
BioNTech : Invitation to the Annual General Meeting 2024 - Form 6-K PU
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer GL
BioNTech Announces Planned Retirement of Sean Marett GL
BioNTech Announces Planned Retirement of Sean Marett AQ
DD: tonies SE: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them EQ
Tonies : Managers' transactions Managers' transaction notification PU
DD: tonies SE: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them EQ
DD: tonies SE: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them EQ
Tonies : Managers' transactions Managers' transaction notification PU
DD: tonies SE: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them EQ
DD: Correction of a release from 28/08/2023, 18:00 CET/CEST - tonies SE: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them EQ
Tonies : Managers' transactions Managers' transaction notification PU
DD: tonies SE: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them EQ
BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer GL
BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer AQ
Tonies : Managers' transactions Managers' transactions notice PU
DD: tonies SE: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them EQ
Tonies : Managers' transactions Managers' transaction notice PU
DD: tonies SE: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them EQ
DD: tonies SE: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them EQ
BioNTech : Invitation to the Annual General Meeting 2023 - Form 6-K PU
BioNTech : Joint report of the Management Board of BioNTech SE and the management of BioNTech Individualized mRNA Manufacturing GmbH on the domination and profit and loss transfer agreement pursuant to Sec. 293a of the German Stock Corporation Act PU
BioNTech : Announces Second Quarter Financial Results and Corporate Update - Form 6-K PU
BioNTech : Quarterly Report for the Three and Six Months Ended June 30, 2022 - Form 6-K PU
BioNTech Announces Second Quarter Financial Results and Corporate Update GL
BioNTech Announces Second Quarter Financial Results and Corporate Update GL
Tonies SE : Notification and public disclosure of transactions by persons EQ
Tonies SE : Notification and public disclosure of transactions by persons EQ
BioNTech : Voting Results from BioNTech’s Annual General Meeting 2022 - Form 6-K PU
Voting Results from BioNTech’s Annual General Meeting 2022 GL
Voting Results from BioNTech’s Annual General Meeting 2022 AQ
BioNTech : Invitation to the Annual General Meeting 2022 on June 1, 2022 - Form 6-K PU
MIG Capital leads ?22.5 million Series B financing for Mimi Hearing Technologies EQ
Berlin-based Mimi Hearing Technologies Closes $25 million Series B Funding to Become the World's Largest Platform for Hearing Wellbeing PR
Tonies SE starts trading on the Frankfurt Stock Exchange through successful business combination with 468 SPAC EQ
468 SPAC I SE: 468 SPAC I obtains 100% shareholder approval and 0.02% redemption rate, paving the way for its business combination with Boxine GmbH and listing as tonies SE EQ
OQmented, Technology Leader in MEMS-Based AR/VR Display and 3D Sensing Solutions, Secures USD 9.3M of Funding GL
AiCuris Anti infective Cures : AG Announces Dr. Stefan Oschmann, Former Merck CEO, to Chair the Supervisory Board EQ
BioNTech : Broadens Management Board by Appointing Jens Holstein as CFO (Form 6-K) PU
12NextSee all

Insiders

Picture Helmut Jeggle
Helmut Jeggle

Helmut Jeggle is a businessperson who has been at the helm of 23 different companies. Currently, he occupies the position of Chairman-Supervisory Board of BioNTech SE, Managing Director at AT Newtec GmbH, Co-Managing Director at Jossa Arznei GmbH, Co-Managing Director at Santo Service GmbH, Managing Director at Avitop GmbH, Co-Chief Executive Officer for Neuraxpharm Holding GmbH, Managing Director & Chief Financial Officer at Nx Biotech GmbH, Managing Director at Horus Sentilo Projektentwicklungsgesellschaft mbH, Chief Executive Officer for Salvia GmbH, Co-Managing Director at SWB Holding GmbH (Bayern), Co-Managing Director at A&T Grundstück 1 GmbH, Co-Managing Director at A&T Grundstück 2 GmbH, Co-Managing Director at Palais Berlin 1 GmbH, Chairman-Supervisory Board at AiCuris Anti-infective Cures GmbH, Co-Managing Director at Santo Holding (Deutschland) GmbH, Chief Operating Officer & Co-Managing Director at Athos Service GmbH, Co-Managing Director at Objektgesellschaft Berlin Passauer Straße 5-7 mbH, Co-Managing Director at Objektgesellschaft München Jahnstraße 41 und Klenzestraße, Managing Director at Santo Venture Capital GmbH, Chief Executive Officer & General Partner at ATHOS KG and Managing Director at ATS Beteiligungsverwaltung GmbH. He is also Co-Managing Director at AT Impf GmbH and Managing Director at Apceth Biopharma Manufacturing Co. Gmbh and on the board of 6 other companies. In the past Helmut Jeggle occupied the position of Managing Director at Klinge Pharma GmbH (Bayern), Chairman-Management Board at Sidroga AG, Managing Director at apceth Biopharma GmbH, Head-Business Planning & Analysis at H e x a l AG and Head-Business Planning & Analysis at Sandoz International GmbH. Helmut Jeggle received an undergraduate degree from Neu-Ulm University of Applied Sciences and an MBA from Stuttgart Institute of Management & Technology GmbH.







Picture Helmut Klingl
Helmut Klingl

Helmut Klingl is currently the Chairman at Kampos Vertriebs GmbH.
He was previously a Member-Supervisory Board at Mineralbrunnen Überkingen-Teinach GmbH & Co. KGaA from 2011 to 2019.


Picture Helmut Sattler
Helmut Sattler

Helmut Sattler is currently the Managing Director at Neudoerfler Office Systems GmbH.


Picture Helmut Limbeck
Helmut Limbeck

Helmut Limbeck is currently the CEO and Director-Supervisory Board at Europapier International AG.


No results for this search

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW